Navigation Links
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
Date:9/10/2007

will be available through Sept. 14, 2007.

About TRU-015 and SMIP(TM) Therapeutics

Trubion and Wyeth Pharmaceuticals are developing small modular immunopharmaceutical (SMIP(TM)) therapeutics directed to CD20, an antigen present on B cells. In addition to the ongoing development of TRU-015 for RA, investigational new drug applications have been filed for TRU-015 for systemic lupus erythematosus and non-Hodgkin's lymphoma. Trubion's SMIP drug candidates represent a novel class of immunotherapeutics that the company believes possess enhanced drug properties over monoclonal and recombinant antibodies. SMIP product candidates are novel single-chain polypeptide proteins designed using Trubion's custom drug assembly technology. Trubion's current product candidates bind to specific antigen targets on a cell's surface that have been clinically validated as important in disease management either by existing products or by potential products in clinical trials.

About Rheumatoid Arthritis

RA is a chronic disease, mainly characterized by inflammation of the lining, or synovium, of the joints. It can lead to long-term joint damage, resulting in chronic pain, loss of function and disability. According to Datamonitor, RA is estimated to affect approximately 4.3 million people in the United States, Japan and Europe. In 2006, total reported worldwide sales of protein therapeutics used for the treatment of RA were greater than $9.5 billion.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP custom drug assembly technology. In less than 24 months, the company designed, developed and submitted to the FDA an Investigational New Drug (IND) application for its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatmen
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... AUSTIN, Texas , Sept. 4, 2015  Luminex ... will present at the Morgan Stanley Global Healthcare Conference ... the Grand Hyatt Hotel in New York ... begin at 11:40 a.m. Eastern time on Friday, September ... be accessed at Luminex Corporation,s website at http://www.luminexcorp.com ...
(Date:9/4/2015)... PUNE, India , September 4, 2015 ... "Apheresis Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and ... by Technology and by Product - Global Forecast to ... expected to reach USD 2.5 Billion by 2020, growing ... from 2015 to 2020. Browse 139 ...
(Date:9/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... upcoming Rodman & Renshaw 17 th Annual Global ... New York City .  Dr. Michael ... overview on September 9, 2015. Presentation ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
... Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on ... nervous system (CNS) diseases and trauma, announced today that ... treatment of acute migraine attacks, from the specialist healthcare ... the precise cause of migraines is not fully understood, ...
... Cohera Medical, a rapidly growing medical device company, announced today ... 50 Awards. Cohera Medical was recognized as the 2011 Life ... Executive Officer, Patrick Daly, was named Pittsburgh CEO of the ... by the Pittsburgh Technology Council as a company that is ...
Cached Medicine Technology:Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine 2Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine 3Cohera Medical and CEO Receive Pittsburgh Tech 50 Awards 2Cohera Medical and CEO Receive Pittsburgh Tech 50 Awards 3
(Date:9/4/2015)... ... September 04, 2015 , ... Scalability Experts (SE) announced that ... at this year’s Microsoft Worldwide Partner Conference that was held in Orlando, Florida. ... Winner for Data Platform services, the 2015 HP and Microsoft “Outstanding Frontline Partner” ...
(Date:9/4/2015)... Francisco, CA (PRWEB) , ... September 04, 2015 ... ... Amini, announces that CEREC technology is now available at CitiDent. CEREC is a ... machinery. In addition to saving time for patients by eliminating the need for ...
(Date:9/4/2015)... ... 2015 , ... Mike Day, a former Navy SEAL who was shot 27 ... Championships in Kona on October 10th. , Mike is running the race to raise ... and the cutting-edge treatments that restore their quality of life. More than ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... of personal humidifying medical devices, announced its only mission and research focus: Water ... Research Founder Sharon Kleyne, body water evaporation is becoming dangerously accelerated. As a ...
(Date:9/4/2015)... ... September 04, 2015 , ... The conference program for ... Florida October 9-10, 2015 at the Diplomat Resort & Spa has been announced ... and researchers at the top of their field and will be presenting sessions ...
Breaking Medicine News(10 mins):Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... Awards go to Henry Ford Health System, MSU, ... 2008 Five Michigan researchers whose,work has helped ... research dollars totaling $50,000 through Blue Cross Blue ... Awards., The researchers are from Henry Ford ...
... 2008 Protection against,vaccine-preventable diseases is not only ... clinicians aware of the importance of,complete and timely ... Practice has published a supplement to the April ... your community adequately,protected?, Based on a recently ...
... Characterization of Dry-Patch ... Vaccine -, ... announced it will receive a,cost-reimbursement grant for up to $943,856 from the ... a,patch-based version of the anthrax vaccine., Under the 1-year grant, Iomai ...
... Just Plain Fraudulent Asks Top Acupuncture Physician, ... when you,thought it was safe to get acupuncture ... the right to be shamelessly under qualified. This,time ... ordinary to "cure" asthma,ADD, hot flashes, post-stroke injury, ...
... Two Hospitals in the System - Sentara Heart Hospital ... Beach General Hospital ... - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer of real-time ... today announced that Sentara Heart,Hospital(R) in Norfolk, Virginia and ...
... TAMPA, Fla., April 8, 2008 A Tampa-area ... medical reporting,systems that allows physicians to gain approval ... with patients as a result., As medical ... -- making patients wait longer for procedures and,giving ...
Cached Medicine News:Health News:Researchers Able to Continue their Work to Help Patients Thanks to McDevitt Excellence in Research Awards from Blue Cross Blue Shield of Michigan Foundation 2Health News:Adults Need Protection Against Vaccine-Preventable Diseases, Too 2Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 2Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 3Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 4Health News:SNAP! CRACKLE! POP! Untrained Chiropractors Doing Acupuncture! 2Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 2Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 3Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: